

Rahul Aggarwal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4668050/publications.pdf>

Version: 2024-02-01

21
papers

452
citations

840585

11
h-index

752573

20
g-index

22
all docs

22
docs citations

22
times ranked

439
citing authors

#	ARTICLE	IF	CITATIONS
1	Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009099.	1.6	14
2	Generalizability of FIGARO–DKD and FIDELIO–DKD Trial Criteria to the US Population Eligible for Finerenone. Journal of the American Heart Association, 2022, 11, e025079.	1.6	7
3	Diabetes Screening by Race and Ethnicity in the United States: Equivalent Body Mass Index and Age Thresholds. Annals of Internal Medicine, 2022, 175, 765-773.	2.0	27
4	Comparison of Medicare Advantage vs Traditional Medicare for Health Care Access, Affordability, and Use of Preventive Services Among Adults With Low Income. JAMA Network Open, 2022, 5, e2215227.	2.8	6
5	Association of the Medicare Value-Based Purchasing Program With Changes in Patient Care Experience at Safety-net vs Non–Safety-net Hospitals. JAMA Health Forum, 2022, 3, e221956.	1.0	5
6	Acute pulmonary embolism following recent hospitalization or surgery. Journal of Thrombosis and Thrombolysis, 2021, 52, 189-199.	1.0	2
7	Association Between the Proportion of Black Patients Cared for at Hospitals and Financial Penalties Under Value-Based Payment Programs. JAMA - Journal of the American Medical Association, 2021, 325, 1219.	3.8	46
8	The protective association between statins use and adverse outcomes among COVID-19 patients: A systematic review and meta-analysis. PLoS ONE, 2021, 16, e0253576.	1.1	26
9	Generalizability of DAPA-CKD to the United States. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007875.	0.9	7
10	Racial/Ethnic Disparities in Hypertension Prevalence, Awareness, Treatment, and Control in the United States, 2013 to 2018. Hypertension, 2021, 78, 1719-1726.	1.3	117
11	In-Hospital Mortality for Inpatient Percutaneous Coronary Interventions in the United States. American Journal of Cardiology, 2021, 159, 30-35.	0.7	4
12	Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. JAMA Cardiology, 2021, 6, 1415.	3.0	19
13	Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States. Progress in Cardiovascular Diseases, 2021, 68, 97-98.	1.6	6
14	Colchicine use in patients with COVID-19: A systematic review and meta-analysis. PLoS ONE, 2021, 16, e0261358.	1.1	21
15	U.S. Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 Inhibitor Therapy. Journal of the American College of Cardiology, 2020, 76, 2907-2910.	1.2	5
16	Prevalence of angina and use of medical therapy among US adults: A nationally representative estimate. American Heart Journal, 2020, 228, 44-46.	1.2	8
17	Systemic nature of spinal muscular atrophy revealed by studying insurance claims. PLoS ONE, 2019, 14, e0213680.	1.1	47
18	Heart failure and the discrepancy between trials of intensive blood pressure management: an analysis of individual patient data. Clinical Research in Cardiology, 2018, 107, 565-569.	1.5	2

#	ARTICLE	IF	CITATIONS
19	Intensive Blood Pressure Targets for Diabetic and Other High-Risk Populations. Hypertension, 2018, 71, 833-839.	1.3	17
20	Development of an Algorithm to Identify Patients with Physician-Documented Insomnia. Scientific Reports, 2018, 8, 7862.	1.6	15
21	The MELD-Plus: A generalizable prediction risk score in cirrhosis. PLoS ONE, 2017, 12, e0186301.	1.1	51